In early 2023, the founder of the psychedelic medicine company Lykos Therapeutics met with a potential investor for dinner, feeling out the chemistry for a financial — and personal — relationship that could set the company’s future.
The investor, Protik Basu, was close to leading a huge investment into Lykos, which was on the cusp of bringing to patients a new type of treatment for post-traumatic stress disorder. Rick Doblin, Lykos’ founder, had once hoped to avoid selling any equity in the company at all.
Protik Basu Over the two-and-a-half-hour dinner, the two men bonded over liberation theology, a Christian social justice movement that sought to empower the poor and improve socio-economic disparities. Lykos’ drug midomafetamine, better known as the psychedelic MDMA, was speeding toward the FDA. The company believed it could help the roughly 13 million Americans suffering from PTSD, including everyone from veterans…
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
